Long-term effects of a combination of isoflavones, agnus castus and magnolia extracts on climacteric symptoms and cardiometabolic risk profile in postmenopausal women.

Objective: To evaluate the long-term effects of a combination of isoflavones, agnus castus and magnolia extracts (combined isoflavone compound [CIC]) on climacteric symptoms and cardiometabolic risk in symptomatic postmenopausal women.

Methods: This interventional, prospective study evaluated climacteric symptoms, mood and sleep disorders using the 21-item Greene Climacteric Scale (GCS) and 7-item Insomnia Severity Index (ISI) questionnaires; and cardiovascular, metabolic and thrombotic risk markers at baseline (T0) and after 12 months of CIC treatment (T1).

Results: In healthy postmenopausal women ( = 71), 12-month CIC treatment significantly reduced patient-reported vasomotor symptoms (100% 17%), mood disorders (67% . 25%) and sleep disorders (89% 19%%) (all  < .001) compared with baseline; and significantly improved GCS psychological, somatic, and vasomotor domain scores and ISI sleep disturbance scores (all  < .05). CIC significantly reduced systolic ( = .022) and diastolic blood pressure ( < .001), and heart rate ( < .001); glucose concentrations ( = .018), HOMA index ( = .013), and ALT ( = .035), homocysteine ( = .005) and NT-proBNP ( = .003) levels.

Conclusions: Long-term CIC therapy improved vasomotor symptoms, mood disorders, sleep disorders, hemodynamic measurements and cardiometabolic risk markers in healthy postmenopausal women.

Clinicaltrials.gov Identifier: NCT03699150.